Skip to main content

Unusual presentation of fatal disseminated varicella zoster virus infection in a patient with lupus nephritis: a case report

Abstract

Background

The risk of life-threatening complications, such as visceral disseminated varicella zoster virus (VZV) infection, is greater in immunosuppressed individuals, such as systemic lupus erythematosus (SLE) patients.

Case presentation

Here, a case is reported of a Caucasian woman diagnosed with lupus nephritis and anti-phospholipid syndrome, who was subjected to mycophenolate mofetil and high-dose steroid remission-induction therapy. Two months later she developed abdominal pain followed by a fatal rapid multi-organ failure. As no typical skin rashes were evident, death was initially attributed to catastrophic anti-phospholipid syndrome. However, autopsy and virological examinations on archival material revealed a disseminated VZV infection.

Conclusions

Overall, this case highlights the importance of having a high clinical suspicion of fatal VZV infections in heavily immunosuppressed SLE patients even when typical signs and symptoms are lacking.

Peer Review reports

Background

Varicella-zoster virus (VZV), a member of the family of herpesviridae, remains latent in dorsal roots and autonomic ganglia after a primary infection, but it can always reactivate leading to a secondary infection, which is usually characterized by skin rash and acute neuritis. In some cases, more severe complications may occur especially in immunocompromised patients, where multi-organ involvement can develop with manifestations such as encephalitis, aseptic meningitis, pneumonia and hepatitis [1].

Here, a case is reported of fatal visceral disseminated VZV in a patient affected by systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS) treated with mycophenolate mofetil (MMF) and high-dose glucocorticoids.

Case presentation

A 49-year-old Caucasian woman affected by SLE and APS presented to the Emergency Department complaining of acute onset of abdominal pain. She denied fever, nausea or vomit. Two months earlier, the patient, with no previous medical history, had been hospitalized for deep vein thrombosis. Her vaccination history was as follows: diphtheria, polio, smallpox and tetanus; she had never been vaccinated for chickenpox, measles, mumps or rubella. During that period, she had been diagnosed with both SLE —positive homogeneous antinuclear antibody titer of 1:320 with a homogeneous pattern— and APS —positive lupus anticoagulant—, with multi-organ dysfunction consisting of lupus nephritis with nephrotic syndrome, lung serositis, hemolytic anemia and arthritis. Consequently, the patient had been treated with MMF (1.5 g qd) and prednisone (50 mg qd) by nephrologists. On hospital admission, vitals were normal except for heart rate at 120 bpm. Physical examination revealed petechiae at thorax and limbs. Complete blood count showed low lymphocyte [0.50 × 109/L] and platelet (58 × 109/L) counts. Other serum abnormal laboratory data included decreased levels of immunoglobulin (Ig) G [118 mg/dL (NR:700–1600)] and increased values of aspartate aminotransferase (AST), alanine aminotransferase (ALT) [22x and 13x upper limit of normal (ULN), respectively] and lactate dehydrogenase (LDH) [13x ULN]. Activated partial thromboplastin time [1.5x ULN] and international normalized ratio (INR) [5.9] were prolonged, whereas renal function was normal. At peripheral blood smear, a number of echinocytes and 2–3 schistocytes/high-power field were detected; platelets were normal-sized but decreased (5/high-power field).

All these findings led to the suspicion of catastrophic APS (CAPS). Therefore, methylprednisolone (1 g qd) was started, but the patient’s conditions worsened dramatically as blood tests revealed persistent decrease in platelet count [23 × 109/L] and substantial increase in INR [7.75], LDH [25x ULN] and D-dimer [71x ULN], consistent with a possible disseminated intravascular coagulation (DIC). Therefore, platelet transfusions and fresh frozen plasma were administered. Later on, plasmapheresis and immunoglobulin infusion became necessary. The patient began to show signs of multiple organ failure (MOF) such as acute kidney injury, increasing elevation of liver function tests, glycemia and troponin I, appearance of confusion and, finally, respiratory distress that required intubation. During the procedure, pseudo-membranes, white exudates and diffuse petechiae were detected in the pharynx (consistent with a possible infective exudative pharyngitis). Later on, hypotension and acute onset anemia appeared, and the patient eventually died a few hours later.

At autopsy, diffuse skin petechiae were present. No significant small vessel occlusions could be observed. Pharyngeal mucosa showed ulcerative lesions associated with cytopathic effects of the squamous epithelium (including acantholysis, intranuclear inclusions and cytoplasmic vacuolization), which were suggestive of viral infection (Fig. 1). The liver parenchyma contained areas of coagulative and hemorrhagic necrosis, and hepatocyte nuclei had a diffuse ground-glass appearance, suspicious for viral inclusions. Moreover, occasional multinucleated hepatocytes were observed (Fig. 2). No other significant alterations were present. Being the morphological picture at pharyngeal and liver level consistent with herpesvirus (HV) infection [2], immunohistochemistry was performed with locally available antibodies [i.e. herpes simplex virus 1 (HSV-1) and 2 (HSV-2) and cytomegalovirus (CMV)], but it resulted negative both in liver and in pharynx.

Fig. 1
figure1

Histological findings at autopsy. Pharyngeal mucosa showing acantholytic keratinocytes with intranuclear inclusions (hematoxylin-eosin staining, magnification × 200)

Fig. 2
figure2

Histological findings at autopsy. Hepatic parenchyma with foci of coagulative necrosis, multinucleated hepatocytes (center left and top right) and ground-glass nuclei (hematoxylin-eosin staining, magnification × 200)

In light of these findings and after a multidisciplinary discussion of the case, it was opted to perform virological tests taking in due account the interpretative limitations related to hypogammaglobulinemia and quantitative real-time polymerase-chain reaction assays (PCR; ELITe MGB Kits, ELITech, France) for HV on the plasma samples that had been harvested on the day of death. The most relevant data was a strong VZV positivity (19,600,000 copies/mL) in the absence of concomitant immune activation [IgM index = 0.3 (cut-off > 1); IgG < 10 mIU/mL (cut-off > 150)]. Furthermore, it was found positivity for CMV [serological pattern of reactivation with DNA at 3240 IU/ml], Epstein–Barr virus (EBV) [serological pattern of reactivation with detectable DNA below the lower limit of quantitation (LLQ) of 256 IU/mL] and human herpesvirus 6 (HHV-6) [DNA below the LLQ of 350 IU/mL], whereas samples were negative for HSV-1 and HSV-2 DNA (Fig. 3).

Fig. 3
figure3

Amplification curves of herpesviruses quantitative real-time polymerase-chain reaction assays. On the x-axis the cycle numbers are represented. On the y-axis the fluorescence signals are reported on a logarithmic scale; Rn is the fluorescence of the reporter dye divided by the fluorescence of the passive reference dye. Green lines represent the four internal controls. The other four curves represent the viral targets as indicated in the Figure (i.e. VZV, CMV, EBV, and HHV-6). The horizontal central line is the threshold line

Discussion and conclusions

VZV infection may develop as a primary infection or reactivation, the latter one being usually characterized by skin rash and acute neuritis. Nevertheless, immunocompromised patients may display more severe and atypical manifestations, such as encephalitis, aseptic meningitis, pneumonia and hepatitis, along with disseminated visceral and cutaneous involvement [1]. These manifestations frequently represent a diagnostic challenge, as the clinical picture might be insidious, leading to a difficulty in the administration of a prompt and appropriate treatment [3]. Therefore, it appears mandatory to take into account unusual signs and symptoms, especially since these subjects are at higher risk for the rare, but severe, disseminated VZV infection. Amongst immunosuppressed subjects, SLE patients have been demonstrated to have a particularly high incidence of VZV infection [4, 5]. However, the determinants of this positive association have so far remained unclear, even though a lack of cellular and/or humoral immunity, such as lymphopenia, may be playing a major role [6,7,8]. Another explanation may be that the use of immunosuppressant drugs is itself a risk factor for VZV. Indeed, the use of combination therapies consisting of MMF and high-dose glucocorticoids has been shown to increase VZV susceptibility [9]. This aspect is particularly relevant to our case. Nevertheless, it is noteworthy that, to be the best of our knowledge, large studies examining the incidence of infections in patients with rheumatic illness treated with MMF are still lacking, so that generalizations can not yet be made. Taking into account these limitations, only a few studies suggest an increased incidence of infectious diseases in such patients [10, 11], as MMF is generally considered a safe drug compared to other immunosuppressive treatments, such as cyclophosphamide [12]. So, even if a MMF role in facilitating viral infections is strongly suspected, a regular monitoring of the presence of VZV in rheumatic patients treated with MMF is not yet recommended.

One of the most recent contributions from the Literature on this topic comes from Habuka et al. who recently described a dramatic case of disseminated VZV infection in a patient with lupus nephritis treated with the aforementioned combination regimen, not only highlighting again the possible harmful effect of immunosuppressive drug therapy, but also suggesting a possible connection between being Asian and experiencing worse outcomes [13]. Although these elements make that case similar to ours, here it is shown an unprecedented case in a Caucasian subject. Moreover, our patient presented with a rarely found combination of disseminated VZV infection and MOF. Another peculiarity of our case is that the patient did not show any signs or symptoms suggestive of VZV infection, when this latter is usually accompanied by cutaneous manifestations, which help make a correct diagnosis. The only complaint reported by the patient was in fact abdominal pain. This symptom is generally considered uncommon and it has always been reported as being concomitant with or, at least, preceding skin manifestations [14]; it is generally considered to occur due to direct viral infection of the enteric nervous system, from at least two different pathways: viremia, in which circulating T cells carry VZV, and axonal transport from dorsal root ganglia [14, 15]. Coming back to our patient, it is possible that she did not have the time to manifest typical skin signs. Not surprisingly, the initial diagnosis failed to recognize viral infection. The differential diagnosis was in fact between acute DIC and CAPS. However, since a clear confirmation of small vessel occlusion was lacking at autopsy, the final cause of death was attributed to MOF secondary to severe sepsis, the latter one being likely also the cause of the severe progressive thrombocytopenia.

Another distinctive feature of this case is that, while autopsy revealed signs of viral infection almost exclusively in the pharynx and liver, blood PCR assays on archival material showed an extremely high viral VZV load. Unfortunately, it is not known how much time went by from the first infection/reactivation to sample collection. In any case, considering that the virological tests were performed 3 weeks later, it is tempting to speculate that there should have been an even higher viral load at the collection time. Thus, VZV serology seems to indicate a recent first infection to which the patient was not able to react, probably due to a severe immunosuppression state, as suggested by hypogammaglobulinemia and lymphopenia (although, at least for the latter one, viral infection cannot be excluded as a contributory cause).

In this patient, the microbiological pattern was further complicated by the occurrence of multiple HV infections concomitant with VZV. These coreactivations are usually associated with poorer outcomes [16, 17]. Among the most commonly reactivated HV, CMV and EBV and, to a lesser extent, also HSV-1, HHV-6 and VZV have been reported [18, 19]. Alternatively, reactivated HV can directly transactivate other latent viruses. As an example, it is known that HHV-6A can reactivate EBV through a BamHI Z fragment leftward open reading frame (BZFL)-1-dependent mechanism, or through the activation of the Zebra promoter by a cyclic AMP-responsive element [20, 21]. Thus, it is apparent that being able to differentiate between clinically significant and latent viral burden is of the utmost importance when dealing with immunosuppressed patients. In this regard, quantitative PCR assays can provide valuable help. In our patient, although the CMV viral load was not as high as that of VZV, it reached threshold values usually recommended for the initiation of preemptive therapy. In contrast, EBV and HHV-6 viremias were below the LLQ, so it was not possible to determine whether they corresponded to true latent virus reactivations, as it was suggested by the concomitant serological responses.

In conclusion, our investigation calls for increased awareness about the unpredictable complications caused by reactivations of specific latent infections under strong immunosuppression: prompt clinical diagnosis might be challenging, so early viral detection is highly recommended [3]. This is because a high index of suspicion on the part of the clinician to monitor for the presence of VZV in MMF-treated patients could result in appropriate timely treatment with acyclovir and better patient outcomes.

Availability of data and materials

All data generated during the survey of this case are included in this published article. The medical file and the histological archive of the patient are available from the corresponding author on reasonable request.

Abbreviations

VZV:

Varicella-zoster virus

HV:

Herpesvirus

SLE:

Systemic lupus erythematosus

APS:

Anti-phospholipid syndrome

MMF:

Mycophenolate mofetil

Ig:

Immunoglobulin

AST:

Aspartate aminotransferase;

ALT:

Alanine aminotransferase

ULN:

Upper limit of normal

LDH:

Lactate dehydrogenase

INR:

International normalized ratio

CAPS:

Catastrophic anti-phospholipid syndrome

DIC:

Disseminated intravascular coagulation

MOF:

Multiple organ failure

HSV-1:

Herpes simplex virus 1

HSV-2:

Herpes simplex virus 2

CMV:

Cytomegalovirus

PCR:

Polymerase-chain reaction

EBV:

Epstein–Barr virus

LLQ:

Lower limit of quantitation (LLQ)

HHV-6:

Human herpesvirus 6

BZFL:

BamHI Z fragment leftward open reading frame

References

  1. 1.

    Gnann JW Jr. Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis. 2002;186(Suppl 1):91–8.

    Article  Google Scholar 

  2. 2.

    Nikkels AF, Delvenne P, Sadzot-Delvaux C, Debrus S, Piette J, Rentier B, et al. Distribution of varicella zoster virus and herpes simplex virus in disseminated fatal infections. J Clin Pathol. 1996;49:243–8.

    CAS  Article  Google Scholar 

  3. 3.

    Lewis D, Schlichte M, Dao H. Atypical disseminated herpes zoster: management guidelines in Immunocompromised patients. Cutis. 2017;100:321–324,330.

    PubMed  Google Scholar 

  4. 4.

    Borba EF, Ribeiro AC, Martin P, Costa LP, Guedes LK, Bonfá E. Incidence, risk factors, and outcome of herpes zoster in systemic lupus erythematosus. J Clin Rheumatol. 2010;16:119–22.

    Article  Google Scholar 

  5. 5.

    Sayeeda A, Al Arfaj H, Khalil N, Al Arfaj AS. Herpes zoster infections in SLE in a University Hospital in Saudi Arabia: risk factors and outcomes. Autoimmune Dis. 2010. https://doi.org/10.4061/2010/174891.

  6. 6.

    Rondaan C, de Haan A, Horst G, Hempel JC, van Leer C, Bos NA, et al. Altered cellular and humoral immunity to varicella-zoster virus in patients with autoimmune diseases. Arthritis Rheumatol. 2014;66:3122–8.

    CAS  Article  Google Scholar 

  7. 7.

    Park HB, Kim KC, Park JH, Kang TY, Lee HS, Kim TH, et al. Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol. 2004;31:2151–5.

    PubMed  Google Scholar 

  8. 8.

    Chen D, Li H, Xie J, Zhan Z, Liang L, Yang X. Herpes zoster in patients with systemic lupus erythematosus: clinical features, complications and risk factors. Exp Ther Med. 2017;14:6222–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Chakravarty EF, Michaud K, Katz R, Wolfe F. Incidence of herpes zoster among patients with systemic lupus Erythematosus. Lupus. 2013;22:238–44.

    CAS  Article  Google Scholar 

  10. 10.

    Meirinhos T, Mariz E, Castro Ferreira I, Neto R, Pereira E, Costa L. AB0424 Retrospective Evaluation of Mycophenolate Mofetil Infectious Side Effects on Lupus Nephritis Patients. Ann Rheum Dis. 2016. https://doi.org/10.1136/annrheumdis-2016-eular.5961.

  11. 11.

    Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus. 2001;10:606–11.

    CAS  Article  Google Scholar 

  12. 12.

    Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, et al. Treatment for lupus nephritis. Cochrane Database Syst Rev. 2012. https://doi.org/10.1002/14651858.CD002922.pub3.

  13. 13.

    Habuka M, Wada Y, Kurosawa Y, Yamamoto S, Tani Y, Ohashi R, et al. Fatal visceral disseminated varicella zoster infection during initial remission induction therapy in a patient with lupus nephritis and rheumatoid arthritis-possible association with mycophenolate mofetil and high-dose glucocorticoid therapy: a case report. BMC Res Notes. 2018;11:165.

    Article  Google Scholar 

  14. 14.

    Okuma HS, Kobayashi Y, Makita S, Kitahara H, Fukuhara S, Munakata W, et al. Disseminated herpes zoster infection initially presenting with abdominal pain in patients with lymphoma undergoing conventional chemotherapy: a report of three cases. Oncol Lett. 2016;12:809–14.

    CAS  Article  Google Scholar 

  15. 15.

    Balkis MM, Ghosn S, Sharara AI, Atweh SF, Kanj SS. Disseminated varicella presenting as acute abdominal pain nine days before the appearance of the rash. Int J Infect Dis. 2009;13:e93–5.

    Article  Google Scholar 

  16. 16.

    Curley MJ, Hussein SA, Hassoun PM. Disseminated herpes simplex virus and varicella zoster virus coinfection in a patient taking thalidomide for relapsed multiple myeloma. J Clin Microbiol. 2002;40:2302–4.

    Article  Google Scholar 

  17. 17.

    Lopez Roa P, Hill JA, Kirby KA, Leisenring WM, Huang ML, Santo TK, et al. Coreactivation of human Herpesvirus 6 and Cytomegalovirus is associated with worse clinical outcome in critically ill adults. Crit Care Med. 2015;43:1415–22.

    CAS  Article  Google Scholar 

  18. 18.

    Grinde B. Herpesviruses: latency and reactivation - viral strategies and host response. J Oral Microbiol. 2013. https://doi.org/10.3402/jom.v5i0.22766.

  19. 19.

    Weinberg A, Bloch KC, Li S, Tang YW, Palmer M, Tyler KL. Dual infections of the central nervous system with Epstein-Barr virus. J Infect Dis. 2005;191:234–7.

    Article  Google Scholar 

  20. 20.

    Cuomo L, Angeloni A, Zompetta C, Cirone M, Calogero A, Frati L, et al. Human herpesvirus 6 variant a, but not variant B, infects EBV-positive B lymphoid cells, activating the latent EBV genome through a BZLF-1-dependent mechanism. AIDS Res Hum Retrovir. 1995;11:1241–5.

    CAS  Article  Google Scholar 

  21. 21.

    Flamand L, Menezes J. Cyclic AMP-responsive element-dependent activation of Epstein-Barr virus zebra promoter by human herpesvirus 6. J Virol. 1996;70:1784–91.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We are grateful to Prof. Marcello Arsura for lexical support.

Funding

This study was funded by the Italian Ministry of Education, University and Research (MIUR) program “Departments of Excellence 2018-2022”, AGING Project – Department of Translational Medicine, Università del Piemonte Orientale. The funder had no role in study design, collection, analysis and interpretation of data, or preparation of the manuscript.

Author information

Affiliations

Authors

Contributions

VV, AC, and CS2 analyzed and interpreted the patient data comprehensively. CS2, SF and MQ managed the patient. ML and CS1 performed and interpreted the histological examinations. PR performed and interpreted serovirological and molecular biology analyses. VV and CS2 drafted the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Carlo Smirne.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Written informed consent to publish the case was obtained from the next of kin of the patient (concerning his relative’s personal or clinical details along with any identifying images to be published in this study).

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vassia, V., Croce, A., Ravanini, P. et al. Unusual presentation of fatal disseminated varicella zoster virus infection in a patient with lupus nephritis: a case report. BMC Infect Dis 20, 538 (2020). https://doi.org/10.1186/s12879-020-05254-6

Download citation

Keywords

  • Varicella zoster virus
  • Herpesviruses
  • Systemic lupus erythematosus
  • Immunosuppression
  • Multiple virus reactivations
  • Latent virus infections
  • Mycophenolate mofetil
  • Steroid therapy